CTOs on the Move

WCG IRB

www.wcgirb.com

 
WCG is the world`s leading provider of solutions that measurably improve the quality and efficiency of clinical research. Comprised of two divisions, the industry`s first central IRB – WCG IRB – and first clinical services organization, WCG enables biopharmaceutical companies, CROs, and institutions to advance the delivery of new treatments and therapies to patients, while maintaining the highest standards of human participant protection.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.wcgirb.com
  • 1019 39th Avenue South East Suite 120
    Puyallup, WA USA 98374
  • Phone: n/a

Executives

Name Title Contact Details
Paul Mancinelli
 Chief Technology Officer Profile

Similar Companies

Midwest Eye Consultants

Midwest Eye Consultants provides total eye care from eye health exams to the treatment of eye diseases. See our locations page to find an office near you.

H.D. Smith Wholesale Drug Co.

Headquartered in Springfield, Illinois, H. D. Smith is among the largest national full-line, full-service wholesalers providing a complete line of pharmaceuticals, OTCs, HBAs, home healthcare products, durable medical equipment, seasonal merchandise and a wide array of marketing programs to retail pharmacies, regional chains and health systems.

Cylene Pharmaceuticals

Cylene Pharmaceuticals Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Quartesian

Quartesian delivers quality, expertise, and speed so you can master your data to take control of your clinical trial.

Intra-Cellular Therapies

Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer`s disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being developed for the treatment of CNS and non-CNS indications.